Neurognathostomiasis is a severe form of human gnathostomiasis which can lead to disease and death. Diagnosis of neurognathostomiasis is made presumptively by using clinical manifestations. Immunoblotting, which recognizes antigenic components of molecular mass 21 kDa and 24 kDa in larval extracts of Gnathostoma spinigerum (Gs 21/24), has high sensitivity and specificity for diagnosis of neurognathostomiasis. However, only very small amounts of the Gs 21/24 antigens can be prepared from parasites harvested from natural or experimental animals. To overcome this problem, we recently produced a recombinant matrix metalloproteinase (rMMP) protein from G. spinigerum. In this study, we evaluated this rMMP alongside the Gs 21/24 antigens for serodiagnosis of human neurognathostomiasis. We studied sera from 40 patients from Srinagarind Hospital, Khon Kaen University, Thailand, with clinical criteria consistent with those of neurognathostomiasis, and sera from 30 healthy control adults from Thailand. All sera were tested for specific IgG antibodies against both G. spinigerum crude larval extract and rMMP protein using immunoblot analysis. The sensitivity and specificity for both antigenic preparations were all 100%. These results show that G. spinigerum rMMP protein can be used as an alternative diagnostic antigen, in place of larval extract, for serodiagnosis of neurognathostomiasis.
Human gnathostomiasis is an important food-borne helminthic zoonosis caused by spirurid nematodes of the genus Gnathostoma and is endemic in Asia and the Americas [1] [2] [3] . Generally gnathostomiasis is not a life-threatening disease, fatalities being recorded only occasionally among neurognathostomiasis patients [2, 4] . Gnathostoma spinigerum has been reported as the only causative agent for neurognathostomiasis in Southeast Asia, particularly Thailand, the only region where this condition exists [4] . Human infection occurs by consuming raw or inadequately cooked foods, e.g. freshwater fishes, frogs, and chickens, which harbor Gnathostoma advanced third stage larvae (AL3). The larvae migrate to the CNS to cause radiculomyelitis or radiculoencephalomyelitis. Subarachnoid hemorrhage (SAH) can occur, sometimes leading to death [5] [6] [7] . Definitive diagnosis of helminthic CNS infections is difficult. The chances of recovering worm specimens are extremely low [4] . The most reliable diagnostic tool is a serologic test, such as immunoblotting using Gnathostoma AL3 extract that is known to contain 2 antigenic peptides with approximate molecular masses of 21 kDa and 24 kDa [8] . However, only tiny quantities of the specific antigens can be obtained from AL3, and laboratory maintenance of the life-cycle to ensure supply is expensive and time consuming. Therefore, we evaluated the diagnostic use of a recombinant matrix metalloproteinase (rMMP) protein [9] for immunodiagnosis of neurognathostomiasis. Recombinant proteins can be produced in large quantities whenever required. This study prospectively enrolled 40 patients who were sus- [8] . The major criteria were eating raw food possibly contaminated with living Gnathostoma infective stage larvae from an endemic area, and acute-onset neurologic symptoms. Minor criteria were migratory swelling, radicular pain, blood eosinophilia > 500 cells/mm 3 , eosinophils in cerebrospinal fluid, and suggestive results by neuroimaging [7, 10, 11] . A presumptive diagnosis of neurognathostomiasis was made when a person satisfied both of the major criteria and 1 of the minor criteria. All patients were positive for the 21 kDa and/or 24 kDa antigenic components of the G. spinigerum larval extract (Gs 21/24) but yielded negative serologic results for angiostrongyliasis [12] , paragonimiasis [13] , and fascioliasis [14] in immunoblotting, and also negative for cysticercosis [15] by ELISA. The negative control group included 30 samples from healthy adult volunteers who at the time of blood collection were found to be free from any intestinal parasite after stool examination using the formalin ethyl acetate concentration technique [16] . Informed consent was obtained from all human adult participants. The study protocol was approved by the Khon Kaen University Ethics Committee for Human Research (HE541293).
The rMMP protein was constructed from a cDNA encoding MMP protein of G. spinigerum larvae, cloned and expressed in Escherichia coli [9] . It had a molecular mass of approximately 102 kDa with the fusion-tagged protein. The G. spinigerum larval extract [17] and purified fusion-tagged rMMP protein [9] were separately characterized by SDS-PAGE followed by immunoblotting as previously described [17] with some modifications. The membranes blotted with G. spinigerum larval extract and rMMP were incubated in 1% skimmed milk in PBS, pH 7.5, containing 0.1% Tween-20 (PBST) for 30 min for blocking non-specific binding sites, washed, and then the membrane was cut into ~3 mm wide strips (9.8 µg protein/strip) for both antigens. Each strip was incubated with 1:100 diluted individual human serum sample (in 1% skimmed milk in PBS, pH 7.5) for 2 hr at room temperature. For immunoblotting against the rMMP protein, each serum sample was absorbed with E. coli lysate before use. The membranes were washed with 1% skimmed milk in PBST (5 times each) and incubated with goat anti-human IgG (H+L) HRP conjugate (Invitrogen) at a dilution of 1:4,000 in 1% skimmed milk in PBST, for 2 hr at room temperature. After 5 washes with 1% skimmed milk in Representative immunoblotting patterns (A, B) when human sera were tested against the Gnathostoma spinigerum larval extract containing 21 kDa and 24 kDa antigenic components (Gs 21/24) (A), and when the same sera were tested against the recombinant matrix metalloproteinase (rMMP) protein (B). Antigens were probed with the sera from pooled negative controls (N), pooled human gnathostomiasis patients (P), clinically confirmed neurognathostomiasis patients (1-10) and healthy controls (11) (12) (13) (14) (15) . The arrows indicate the specific immunoreactive bands at approximately 21 kDa and 24 kDa (Gs 21/24) and at approximately 102 kDa (rMMP protein with the fusion-tagged protein).
PBST, the strips were developed with 3,3´-diaminobenzidine tetrahydrochloride and H2O2 as substrate, and the reaction stopped with distilled water. The diagnostic parameters of sensitivity and specificity were calculated as previously described [18] .
Immunoblot analysis employing the G. spinigerum larval extract of 21 kDa and 24 kDa antigenic components (Gs 21/24) (Fig. 1A) and the purified fusion-tagged rMMP protein (Fig. 1B) was evaluated using individual sera from healthy controls and from neurognathostomiasis patients. All serum samples from the neurognathostomiasis patients strongly reacted with both antigens. None of the 30 healthy control sera showed positive seroreactivity. The calculated diagnostic sensitivity and specificity were therefore 100% in each case.
Definitive diagnosis of neurognathostomiasis requires invasive procedures for demonstration of parasites [4] . The procedures need experienced personnel and laboratory support, and cannot be performed in general practice. Practically, diagnosis is made by clinical features, a history of eating parasite-contaminated foods, blood eosinophilia, eosinophils in cerebrospinal fluid, suggestive neuroimaging results, and serological findings especially via immunoblotting using the Gs 21/24 antigens [8] . Our results showed that the rMMP is as good as the Gs 21/24 antigens for serologic diagnosis of human neurognathostomiasis.
As neurognathostomiasis has been reported in Asia, i.e., Thailand, Laos, Japan, Mayanmar, and South Korea, as well as in European travelers returning from endemic areas [4] , the mass production of G. spinigerum rMMP protein creates the potential for development of a serodiagnostic kit, i.e., immunochromatographic test. The method can be used not only for neurognathostomiasis but also for other forms of gnathostomiasis. The supportive diagnosis will help clinicians for prompt treatment of this harmful disease. Importantly, this diagnostic tool will be helpful for neurosurgeons considering management of intracranial hemorrhage patients without conventional invasive therapy.
